It is intended that the award should recognise scientific achievement of young scientists working in the field of allergy and encourage their engagement in further research. Therefore, the award is open to EAACI Junior Members who have conducted their research in a European centre.
The EAACI Allergopharma Research Award was first established in 2000 on the initiative of Allergopharma Joachim Ganzer KG in collaboration with the European Academy of Allergy and Clinical Immunology. It is intended that the award should recognise scientific achievement of young scientists working in the field of allergy and encourage their engagement in further research. Therefore, the award is open to EAACI Junior Members who have conducted their research in a European centre. More information on EAACI Junior Members you will find by clicking here. (“EAACI Junior Membership shall be available to all those who are aged 35 years or less at the time of renewal of their subscription.”)
The award is valued at EUR 10,000 and will be granted to the institution or research organisation the awardee primarily conducts the research for. The awardee will be presented with the EAACI Allergopharma Research Award during the Opening Ceremony of the EAACI Annual Congress each year. Registration to the congress will be supported by the grant.
Applications for 2024 are open.
Submissions close 22 December 2023 (23:59 CET).
1. Any EAACI Junior Member (JM) may apply personally for the award using the online system provided.
2. Applicants can modify the author information, category and core data of their abstract directly in the submission system until the deadline was given. Please be aware that there will be no extension possible.
3. By submitting this application, I understand that my application, including names, is stored electronically.
4. Applications will be reviewed by an expert panel of reviewers. Acceptance of the submitted application is at the discretion of the Review Panel. Allergopharma will not be involved or take any influence on the decision-making process.
5. Declaration of Conflict of Interest: EAACI is committed to ensuring the integrity of its scientific, educational, and research programmes. Applications require disclosure of any financial or other interest that might be construed as resulting in an actual, potential, or apparent conflict.
1. Motivation letter/Executive summary: A summary of the applicant’s major accomplishments highlighting their impact on the field
2. A complete curriculum vitae
3. List of up to three individual articles that support the quality and originality of the research clearly identifying the concept(s) developed
4. Upload of 1 to 3 most relevant publications in PDF format
5. A complete bibliography of publications with key publications identified. In case of multiple authors, the applicant’s specific contribution to the publication should be briefly discussed
6. Cumulative citation factor and Impact factor
7. At least two supporting letters, at least one of which should be provided by a supporter outside the applicant’s institution. The letters should specifically support the significant accomplishments of the applicant justifying why the applicant should receive this recognition.
1. The received complete applications will be reviewed by EAACI’s independent scientific award committee.
Please note: For reasons of industry compliance, Allergopharma will not be involved in any way in the selection process.
2. The EAACI Executive Committee selects the awardee in February 2024.
3. Notification of the winner is in late February and the official announcement is during the Opening Ceremony of the EAACI Annual Congress 2024, 31 May, in Valencia. The prize money will be paid to the winner’s home institution by the end of July 2024.
EAACI Allergopharma Award 20232023Marine-Alexia Lefevre – PhDTo be presented at EAACI Hybrid Congress 2023, on 9 June 2023 to the winner, Marine-Alexia Lefevre – PhD The awarded research project: “Contact dermatitis: from biomarker discovery to the development of new molecular diagnostic approaches” and her research focuses on the management of drug hypersensitivity (immediate and delayed reactions), hymenoptera allergies and inflammatory skin diseases (atopic dermatitis, contact dermatitis, urticaria…) as well as mast cell diseases. With a specific interest in the pathophysiology of inflammatory skin diseases, in particular contact dermatitis, and in the development of new molecular diagnostic approaches for a more personalized management of these diseases her teams work have been able to identify and validate biomarkers of allergic contact dermatitis, which can be used to strengthen the clinical diagnosis of eczema but also to optimize the interpretation of allergological assessments.
For more information please contact:
Telephone: +41 44 205 55 33